Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies

Condition(s) studied

Study summary

This is a multicenter, cohorts study to collect information from patients diagnosed with early-stage invasive breast cancer who have been previously included in a neoadjuvant or adjuvant clinical trial of the GEICAM group.

Patients will be included in this study from the moment of completion of the follow-up of the studies of origin and will be followed for approximately 30 years

Eligibility

Primary outcome measure(s)

• Event Free Survival (EvFS) in neoadjuvant studies. — Throughout the whole follow up. Up to 30 years from the beginning of the Study approximately.
  The EvFS, is defined as the time from the randomization of the patients in the studies of origin, to the date of one of the following events: * Disease progression during neoadjuvant treatment. * Disease relapse (local, regional or distant) after curative surgery. * Second primary tumors * Death due to any cause.
• Disease Free Survival (DFS) in adjuvant studies. — Throughout the whole follow up. Up to 30 years from the beginning of the Study approximately.
  DFS is defined as the time from the date of randomization of patients in the studies of origin, to the date of one of the following events: * Disease relapse (local, regional or distant) after curative surgery. * Second primary tumors * Death due to any cause.

Trial sites (73)

+ 33 more sites — see the full list on the official registry below.

More Spanish Breast Cancer Research Group trials in Spain